Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nature'S Fusions LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, ROSSI, JULIA ANNE LORRAIN. The prosecution is further localized within 1 distinct art unit. ROSSI, JULIA ANNE LORRAIN is identified as the busiest examiner, holding 1 pending office action.
Because the entire pending portfolio consists of 1 pending office action, the company's legal strategy is highly focused. The involvement of only 1 distinct examiner and 1 distinct art unit means there is no variability in examination style across the current workload. Practitioners should tailor their approach specifically to the preferences of ROSSI, JULIA ANNE LORRAIN. The data shows that this 1 distinct examiner has total oversight of the company's active matters in the Biotechnology & Pharmaceuticals sector. This concentration simplifies the prosecution landscape but increases the impact of a single examiner's perspective.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19038867 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | ROSSI, JULIA ANNE LORRAIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19038867 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | ROSSI, JULIA ANNE LORRAIN | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19038867 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | ROSSI, JULIA ANNE LORRAIN | 1615 | §103§112 | Non-Final OA | — | Pending | Jan 28, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNature'S Fusions LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Julia Anne Lorrain Rossi has the most, with 1 of Nature'S Fusions LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
